Who says we won't be, we are not invited so there is no time sensitivity, we won't be double booked. Love the 'owners of the company' line btw, very funny, very up yourself.
It's definitely only worth 2bn as a company (/sarcasm)
II has for months had it flipping to having the 16.3p value or 0 value, sometimes showing SP changes. I assume the system struggles with this scenario (it really shouldn't).
I suppose they could do it by simply stopping people adding more than 100k, what happens after that is the free market.
I've thought about it, not many options, best options exist before Avacta increases. Tax is tax, it happens, better to be in the position to have to pay it than to not be in that position.
Apparently expressed in the stroma that surrounds the tumour and connects it to the body (as protects from immune system) , so not mobile.
I expect they'll be listening, and talking to others later. On the day those that have actually got the data will be talking. They might have something to say about the implications but they'd probably not have seen much before that day.
Marked reduction does not equal medically none. However is it good enough that side effects are a minor nuisance? But one of the important of cardiotoxicity is perhaps without side effect.
An opinion that in option 1 or 4, at the lower dosage levels nearly as much ava6000 would be coming out as going in, would the safety committee allow this to escalate. This may apply to 2 at the lower levels as well.
Your point 3, the mouse models were 16x in TME for 4x the dose (from memory), so if it is near that, then that's a win, but with lower FAPa circulating in humans than in mice, that multiplier will be higher in my opinion.
Touk a different test will likely need a different TT. There is zero benefit to having an ex employee at that level and on the supplier side, not the customer side, it would be far more beneficial for Abingdon to have an employee in Avacta.
And to answer your original question, this is why it wasn't posted here because it's an irrelevance.
Worse it's something that would grow into there's a link, and then disappointment when it didn't materialise, as there would be a collective, or purposeful, forgetting of how the link was formed.
Timster as might any manufacturer, mostly likely ones that launch already have relationhships with.
I'm sure that Alastairs dog walkers, brothers, mate's boss has a friend at Abingdon as well.
The money is out there, either in agreements or as a BO/TO. And they are not the only one.
before anyone makes anything of it, THE VALIUES ARE GOING DOWN, PAAAANNNNIIIC!
Touk, you have a go at people for talking about the future in terms of prices etc. which are actually of interest and an outcome of success. Then you try and highlight someone moving jobs? Not at a strategic leader level, just a senior scientist. Get a grip on reality, trials going well will eventually increase the SP, someone leaving and starting somewhere else will very likely have no impact.
But they are hilarious!
Hanoi, I don't think the premium pricing is that awquard to talk about, as the cost of managing the side effects will be reduced, so you could increase the cost but still leave it as cost neutral, and time beneficial in terms of clinic time, leaving those professionals free to deal with others. Nett impact to the hospital increased billing, nett cost to insurers zero increase, with a better patient journey. No one loses.
My dad died of prostate cancer, (wouldn't go to doctors for hardly anything), symptoms weakening leg strength (possibly), night time peeing (but he drank 4-5 pints of beer a night), probably other symptoms I wasn't aware of.
Mines large but the right texture on the surface, I also cycle a lot so PSA is not a great test for me.
Get tested, finger up bum if needed, honestly it's not that bad (unless your doc has giant sausage fingers), the docs should not be adverse to doing it.
BSFA before Ivy, seems to be a better product imo
very long? about normal really.
personally I won't be holding anything for any period of time in a new owner, there's too much risk in their background (which I won't understand, look at the talc cancer payout last year, is one of those hidden in the new owner?), and too little reward ongoing, to hold a single stock in what I hope would be £100'sk they might double in the best case. Any divi I could equal or exceed in a fund/trust and reduce the risk dramatically by spreading the load, typical divi for bio is 2-3%? that's not even matching inflation.